GlassScriptPhysician profile
Rafid J Kouz
NPI 1346272994
$17,982.65
in general payments reported to CMS, 2019-2025
52 companies · $5,965 in 2025
The $5,965 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,738 · 2020: $1,072 · 2021: $546 · 2022: $2,211 · 2023: $3,166 · 2024: $3,285 · 2025: $5,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,589 · Consulting Fee: $5,590 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,589.25 |
| Consulting Fee | $5,590.00 |
| Education | $236.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $3,276.83 | 2021-2025 | Tecartus, Yescarta |
| Astrazeneca Pharmaceuticals LP | $2,875.65 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Geron Corporation | $2,214.84 | 2025 | Imetelstat |
| Merck Sharp & Dohme LLC | $988.51 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $834.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $821.58 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $681.28 | 2019-2023 | Adcetris, Padcev |
| Sanofi-Aventis U.S. LLC | $650.00 | 2020-2021 | |
| Celgene Corporation | $550.07 | 2019-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $528.02 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $512.90 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $403.06 | 2019-2025 | |
| Genentech USA, INC. | $266.74 | 2019-2024 | Phesgo, Itovebi, Tecentriq Hybreza |
| Astellas Pharma US INC | $260.65 | 2019-2025 | Vyloy, Xospata |
| Regeneron Healthcare Solutions, INC. | $193.05 | 2023-2025 | Libtayo |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $192.53 | 2019-2025 | |
| Amgen INC. | $192.16 | 2019-2025 | Blincyto, Kyprolis, Xgeva |
| Incyte Corporation | $157.79 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Emd Serono, INC. | $152.68 | 2023-2024 | Bavencio |
| Novartis Pharmaceuticals Corporation | $138.49 | 2019-2025 | |
| Mirati Therapeutics, INC. | $132.39 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $125.18 | 2024-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $124.98 | 2019-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $122.69 | 2021-2025 | Qinlock, Tgct, Romvimza |
| Takeda Pharmaceuticals U.S.A., INC. | $114.49 | 2019-2024 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $102.90 | 2022-2025 | |
| Daiichi Sankyo INC. | $101.26 | 2022-2024 | Enhertu |
| Comsort, INC | $100.00 | 2019 | |
| Eisai INC. | $99.68 | 2020-2025 | |
| Coherus Oncology, INC. | $98.59 | 2024-2025 | Loqtorzi |
| Array Biopharma INC | $90.07 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $88.99 | 2022-2024 | |
| Adc Therapeutics America, INC. | $87.39 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $83.81 | 2023-2025 | Onivyde, Somatuline Depot |
| Exelixis INC. | $68.17 | 2019-2023 | Cabometyx |
| Clovis Oncology, INC. | $61.94 | 2019 | |
| Glaxosmithkline, LLC. | $54.19 | 2024-2025 | Jemperli, Zejula |
| Lilly USA, LLC | $51.35 | 2024 | Jaypirca, Retevmo, Verzenio |
| Syndax Pharmaceuticals, INC. | $49.61 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $39.30 | 2021-2022 | |
| Stemline Therapeutics INC. | $39.17 | 2024 | Orserdu |
| Karyopharm Therapeutics INC. | $32.06 | 2024 | Xpovio |
| Immunogen, INC. | $29.04 | 2023 | Elahere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.82 | 2019-2025 | |
| Sobi, INC | $26.10 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.95 | 2020 | |
| Tesaro, INC. | $25.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $22.80 | 2019 | |
| Epizyme, INC. | $20.15 | 2020 | |
| Rigel Pharmaceuticals, INC. | $17.70 | 2024 | Rezlidhia, Tavalisse |
| Tg Therapeutics, INC. | $15.94 | 2021 | |
| Taiho Oncology, INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafid Kouz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.